aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated for the treatment of patients with locally advanced
, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.
What an amazing opportunity. RISK 5% REWARD 22% 4.44 RISK TO REWARD RATIO
Enough cash on hand ~$720M cash (9/30/20) to last 3 years of R&D
2021 - Year to get some FDA News - HUGE POTENTIAL MARKET FOR CANCER TREATMENT
Research/ Study showing promise.
Developing Iovance manufacturing facility plans for commercialization 75 Million$ Investment scheduled for completion this year.